Efficacy and safety of tenecteplase in the treatment of acute ischemic stroke： a meta-analysis

FENG Xinyu; WANG Min; GUO Wenjun; LI Yuntao

doi:10.6039/j.issn.1001-0408.2023.09.18

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of tenecteplase in the treatment of acute ischemic stroke： a meta-analysis

更新时间：2023-11-06

- Efficacy and safety of tenecteplase in the treatment of acute ischemic stroke： a meta-analysis
- ZHONGGUO YAOFANG Vol. 34, Issue 9, Pages: 1119-1125(2023)
- 作者机构：
  
  1.南京医科大学第二附属医院神经内科，南京　210011
  2.南京医科大学第二附属医院全科医学，南京　210011
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.09.18
  CLC： R972+.6;R743.32
- Published：15 May 2023，
  
  Received：24 October 2022，
  
  Revised：02 March 2023，
扫描看全文
凤心雨,王敏,郭文军等.替奈普酶治疗急性缺血性脑卒中疗效及安全性的Meta分析 ^Δ[J].中国药房,2023,34(09):1119-1125.

FENG Xinyu,WANG Min,GUO Wenjun,et al.Efficacy and safety of tenecteplase in the treatment of acute ischemic stroke： a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(09):1119-1125.
凤心雨,王敏,郭文军等.替奈普酶治疗急性缺血性脑卒中疗效及安全性的Meta分析 ^Δ[J].中国药房,2023,34(09):1119-1125. DOI： 10.6039/j.issn.1001-0408.2023.09.18.

FENG Xinyu,WANG Min,GUO Wenjun,et al.Efficacy and safety of tenecteplase in the treatment of acute ischemic stroke： a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(09):1119-1125. DOI： 10.6039/j.issn.1001-0408.2023.09.18.

摘要

目的

系统评价替奈普酶用于治疗急性缺血性脑卒中（AIS）的疗效和安全性，为临床合理选择静脉溶栓药物提供循证依据。

方法

计算机检索PubMed、Embase、the Cochrane Library、Web of Science、Sinomed、中国知网、万方数据库和维普网，收集替奈普酶对比阿替普酶（对照）治疗AIS疗效与安全性的随机对照试验，检索时限均为建库起至2022年6月。由2位评价员独立筛选文献，从文献中提取资料并评价纳入研究的偏倚风险，采用Stata 15软件对数据进行Meta分析。

结果

最终纳入8篇文献，共计2 129例患者。Meta分析结果显示，0.25 mg/kg（中剂量）替奈普酶组患者早期神经功能改善率[OR（95%CI）＝2.44（1.09，5.46），

＝0.030]、神经功能恢复良好率（静脉溶栓治疗90 d后改良Rankin量表评分0～2分）[OR（95%CI）＝1.54（1.00，2.36），

＝0.048]高于阿替普酶组。其余结局指标（包括再通率、再灌注病变百分比、神经功能恢复优异率、出血发生率、症状性颅内出血发生率及90 d内全因死亡率）方面，替奈普酶组与阿替普酶组比较，差异均无统计学意义（

＞0.05）。

结论

与阿替普酶相比，中剂量替奈普酶在早期神经功能改善及神经功能恢复方面有一定优势，且未增加不良事件发生率。

Abstract

OBJECTIVE

To systematically evaluate the efficacy and safety of intravenous bolus of tenecteplase in the treatment of acute ischemic stroke （AIS）， in order to provide evidence-based support for the clinic’s choice of intravenous thrombolytic drugs.

METHODS

Randomized controlled trials （RCTs） about the efficacy and safety of tenecteplase versus alteplase （control） in the treatment of AIS were collected from PubMed， Embase， the Cochrane Library， Web of Science， Sinomed， CNKI， Wanfang Data， and VIP during the inception to June 2022. Two evaluators independently screened the literature， extracted data from the literature， assessed the bias risk of included study， and then conduct meta-analysis by using Stata 15 software.

RESULTS

A total of 8 literature were included， involving 2 129 patients. Meta-analysis results showed that the early improvement rate of neurological function [OR（95%CI）＝2.44（1.09，5.46），

＝0.030] and the good rate of neurological function recovery （modified Rankin scale score 0-2 after 90 days of intravenous thrombolysis treatment） [OR（95%CI）＝1.54（1.00，2.36），

＝0.048] were higher in 0.25 mg/kg tenecteplase group （medium dose） than alteplase group. According to meta-analysis of other outcome indicators （including recanalization rate， percentage of reperfusion lesions， excellent rate of neurological function recovery， the incidence rate of bleeding， the incidence rate of symptomatic intraventricular hemorrhage and all-cause mortality rate within 90 d）， the tenecteplase group had no statistically significant difference with alteplase group （

＞0.05）.

CONCLUSIONS

Compared with alteplase， medium dose of tenecteplase has some advantages in terms of early neurological function improvement and neurological function recovery， and it does not increase the risk of adverse events.

关键词

急性缺血性脑卒中替奈普酶阿替普酶有效性安全性Meta分析

Keywords

tenecteplasealteplaseefficacysafetymeta-analysis

references

National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med，1995，333（24）：1581-1587.

BERGE E，WHITELEY W，AUDEBERT H，et al. European Stroke Organisation （ESO） guidelines on intravenous thrombolysis for acute ischaemic stroke[J]. Eur Stroke J，2021，6（1）：Ⅰ-LⅫ.

彭斌，刘鸣，崔丽英. 与时俱进的新指南：《中国急性缺血性脑卒中诊治指南2018》解读[J]. 中华神经科杂志，2018，51（9）：657-659.

KEYT B A，PAONI N F，REFINO C J，et al. A faster-acting and more potent form of tissue plasminogen activator[J]. Proc Natl Acad Sci USA，1994，91（9）：3670-3674.

PARSONS M，SPRATT N，BIVARD A，et al. A rando- mized trial of tenecteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med，2012，366（12）：1099-1107.

THOMMESSEN B，NAESS H，LOGALLO N，et al. Tenecteplase versus alteplase after acute ischemic stroke at high age[J]. Int J Stroke，2021，16（3）：295-299.

ROALDSEN M B，LINDEKLEIV H，ELTOFT A，et al. Tenecteplase in wake-up ischemic stroke trial：protocol for a randomized-controlled trial[J]. Int J Stroke，2021，16（8）：990-994.

HUANG X Y，CHERIPELLI B K，LLOYD S M，et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke （ATTEST）：a phase 2，randomised，open-label，blinded endpoint study[J]. Lancet Neurol，2015，14（4）：368-376.

BIVARD A，ZHAO H，CHURILOV L，et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit （TASTE-a）：a phase 2，randomised，open-label trial[J]. Lancet Neurol，2022，21（6）：520-527.

LI S Y，PAN Y S，WANG Z R，et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke （TRACE）：a multicentre，randomised，open label，blinded-endpoint （PROBE） controlled phase Ⅱ study[J]. Stroke Vasc Neurol，2022，7（1）：47-53.

LOGALLO N，NOVOTNY V，ASSMUS J，et al. Tenecteplase versus alteplase for management of acute ischaemic stroke （NOR-TEST）：a phase 3，randomised，open-label，blinded endpoint trial[J]. Lancet Neurol，2017，16（10）：781-788.

KVISTAD C E，NAESS H ，HELLEBERG B H，et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway （NOR-TEST 2，part A）：a phase 3，randomised，open-label，blinded endpoint，non-inferiority trial[J]. Lancet Neurol，2022，21（6）：511-519.

HALEY E C，THOMPSON J L P，GROTTA J C，et al. Phase ⅡB/Ⅲ trial of tenecteplase in acute ischemic stroke：results of a prematurely terminated randomized clinical trial[J]. Stroke，2010，41（4）：707-711.

CAMPBELL B C V，MITCHELL P J，CHURILOV L， et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke[J]. N Engl J Med，2018，378（17）：1573-1582.

KATE M，WANNAMAKER R，KAMBLE H，et al. Penumbral imaging-based thrombolysis with tenecteplase is feasible up to 24 hours after symptom onset[J]. J Stroke，2018，20（1）：122-130.

THOMAS G R，THIBODEAUX H，ERRETT C J，et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding[J]. Stroke，1994，25（10）：2072-2079.

NAGARAJA D，GURURAJ G，GIRISH N，et al. Feasi- bility study of stroke surveillance：data from Bangalore， India[J]. Indian J Med Res，2009，130（4）：396-403.

PANDIAN J D，SETHI V，DHILLON R，et al. Is intravenous thrombolysis feasible in a developing country?[J]. Cerebrovasc Dis，2005，20（2）：134-136.

KATSANOS A H，PSYCHOGIOS K，TURC G，et al. Off-label use of tenecteplase for the treatment of acute ischemic stroke：a systematic review and meta-analysis[J]. JAMA Netw Open，2022，5（3）：e224506.

KATSANOS A H，SAFOURIS A，SARRAJ A，et al. Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions：systematic review and meta-analysis[J]. Stroke，2021，52（1）：308-312.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Meta-analysis of efficacy and safety of cabozantinib in the treatment of advanced thyroid cancer

Meta-analysis of efficacy and safety of belimumab in the treatment of childhood-onset systemic lupus erythematosus

Efficacy and safety of new oral anticoagulants in patients with nonvalvular atrial fibrillation after left atrial appendage occlusion：a meta-analysis

Efficacy and safety of low-dose hydrocortisone for the prevention and treatment of bronchopulmonary dysplasia in very premature infants： a meta-analysis

Efficacy and safety of bimatoprost versus latanoprost in the treatment of glaucoma：a meta-analysis

Related Author

ZHU Jing

XIE Ji

ZHAO Ziting

HU Xiaoxia

YU Xin

ZHAI Wensheng

ZHANG Mengmeng

REN Xiangge

Related Institution

Dept. of Oncology， Lanzhou University Second Hospital

Dept. of Geriatrics， Lanzhou University Second Hospital

First Districts of Pediatrics， the First Affiliated Hospital of Henan University of Chinese Medicine

School of Pediatric Medicine， Henan University of Traditional Chinese Medicine

Graduate School of Hebei Medical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰